Jefferson Shreve
Tickers in This Filing
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
5 flagsRepresentative Shreve bought $15,001 - $50,000 in $AMGN on February 24, 2025 — 8 days before the EPIC Act of 2025 (S832) was introduced, which proposes to extend market exclusivity for small-molecule drugs.
Representative Shreve bought $15,001 - $50,000 in $JNJ on February 24, 2025 — 8 days before the EPIC Act of 2025 (S832) was introduced, which proposes to extend market exclusivity for small-molecule drugs.
Representative Shreve bought $15,001 - $50,000 in $MRK on February 24, 2025 — 8 days before the EPIC Act of 2025 (S832) was introduced, which proposes to extend market exclusivity for small-molecule drugs.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $AVGO | Broadcom Inc. - Common Stock (AVGO) [ST] | $100K-$250K | — | — | — | Feb 24, 2025 |
| BUY | $ABBV | AbbVie Inc. Common Stock (ABBV) [ST] | $50K-$100K | — | — | — | Feb 24, 2025 |
| BUY | $XOM | Exxon Mobil Corporation Common Stock (XOM) [ST] | $50K-$100K | — | — | — | Feb 24, 2025 |
| BUY | $GE | GE Aerospace Common Stock (GE) [ST] | $50K-$100K | — | — | — | Feb 24, 2025 |
| BUY | $ADBE | Adobe Inc. - Common Stock (ADBE) [ST] | $15K-$50K | — | $239.31 | — | Feb 24, 2025 |
| BUY | $APD | Air Products and Chemicals, Inc. Common Stock (APD) [ST] | $15K-$50K | — | — | — | Feb 24, 2025 |
| BUY | $AMGN | Amgen Inc. - Common Stock (AMGN) [ST] | $15K-$50K | — | $340.18 | — | Feb 24, 2025 |
| BUY | $APP | Applovin Corporation - Class A Common Stock (APP) [ST] | $15K-$50K | — | — | — | Feb 24, 2025 |
| BUY | $ACGL | Arch Capital Group Ltd. - Common Stock (ACGL) [ST] | $15K-$50K | — | — | — | Feb 24, 2025 |
| BUY | $BC | Brunswick Corporation Common Stock (BC) [ST] | $15K-$50K | — | — | — | Feb 24, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Chief Risk Officer Enforcement and Accountability Act
HR1910 (Chief Risk Officer Enforcement and Accountability Act) is an early-stage bill that codifies existing Fed CRO regulations for large banks, with the structural change of extending requirements to privately held large banks. Publicly traded mega-banks (JPM, BAC, WFC, C, MS, GS) already comply — no new costs. The bill creates incremental demand for compliance consulting and software vendors like ACN, IBM, and ORCL but is in early committee stage with low passage probability.
American Innovation and R&D Competitiveness Act of 2025
HR1990, the American Innovation and R&D Competitiveness Act, would restore immediate expensing for R&D costs, reversing the 2022 tax code change that required 5/15-year amortization. This is an early-stage bill referred to Ways and Means with 81 cosponsors, but if enacted, it would provide a direct 21% tax-rate cash flow benefit annually to every R&D-intensive US company. The largest absolute beneficiaries are mega-cap tech and pharma firms with $10B+ annual R&D budgets.
Ensuring Access to Essential Drugs Act
HR1922 is an early-stage bill referred to committee with no market impact. It would exempt certain orally administered brand-name drugs from Medicare Part D rebate obligations, but no hearings, votes, or further action have occurred since introduction on 2025-03-06.
To amend the Coastal Zone Management Act of 1972 to establish a conclusive presumption that a State concurs to certain activities, and for other purposes.
HR1874 eliminates state-level permitting vetoes under the Coastal Zone Management Act for coastal energy and infrastructure projects, directly accelerating approval timelines for offshore wind, LNG terminals, coastal pipelines, and transmission lines. The bill benefits project developers and lower-risk service providers by removing a major regulatory bottleneck. Real market data shows coastal infrastructure names like NEE and SRE near 52-week highs, while LNG operator LNG has rallied 5.85% in the past week as the market prices in faster permitting.
American Innovation Act of 2025
Bill HR1778 would increase tax deductions for startup costs from $5k to $20k, reducing the net first-year burden for new enterprises. This quantitatively expands the customer base for business-formation beneficiary companies like Intuit ($INTU), Wix ($WIX), and PayPal ($PYPL). Current market data shows these three tickers have experienced near-term price declines (7-day changes of -2.07%, -1.55%, -1.17% respectively), making them cheaper entries ahead of potential bill momentum later in 2026.
EPIC Act of 2025
The EPIC Act of 2025 would extend small-molecule drug exclusivity before Medicare price negotiation from 7 to 11 years for drugs approved after 2028. Despite sector-wide 30-day declines ($MRK -7.18%, $GSK -5.02%, $PFE -4.24%), the bill's early-stage status (referred to Senate Finance Committee) and long legislative path mean no near-term revenue impact. The structural beneficiary is clear: small-molecule-focused pharma pipelines gain 4 additional years of un-negotiated pricing.
Access to Pediatric Technologies Act of 2025
HR1931, the Access to Pediatric Technologies Act, is an early-stage House bill that would require CMS to establish Medicare payment methodologies for qualifying pediatric devices and drugs upon manufacturer request. The bill is referred to two committees with no further action in over a year. It authorizes no direct funding - it creates a regulatory pathway. For med-tech and pharma companies with pediatric product lines (JNJ, ABT, MRK, PFE), the bill is directionally positive but procedurally distant from becoming law.
SPEED for BEAD Act
The SPEED for BEAD Act opens $42.45B in BEAD subsidies to satellite and fixed wireless providers, directly benefiting $SATS and the FWA offerings of $TMUS, $VZ, and $T. The bill is in early legislative stages (referred to committee), but its bipartisan sponsorship and 22 cosponsors signal moderate momentum. $SATS, trading at $122.38 with a 7-day gain of +4.15%, and $TMUS at $197.69 with a 7-day gain of +4.16%, are already showing above-market strength.
Congressional Trade Authority Act of 2025
HR1903 is a procedural bill introduced 13 months ago with zero floor action. It would transfer tariff authority from the President to Congress but has no funding, no scheduled vote, and no market impact in its current state. No ticker warrants a causal chain.
Broadband Grant Tax Treatment Act
The Broadband Grant Tax Treatment Act (HR1873) would exclude BEAD and related broadband grants from federal taxable income, increasing effective grant value for recipients by ~21%. For operators $T, $VZ, $CMCSA, and $LBRDA, this directly improves rural broadband project economics. For equipment suppliers $CIEN and $GLW, it pulls through higher optical and fiber demand. The bill is at early stage (referred to Ways and Means) with a Senate companion. No real price movement attributable to this bill has occurred given its early stage.
Other Filings by Jefferson Shreve
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.